Juergen Eckhardt
SVP and Head @ Leaps by Bayer
Juergen Eckhardt is a Series A investor at Leaps by Bayer focused on Biotechnology and Health Care. Juergen Eckhardt is the Head at Bayer Venture Investments. He is a Director of BlueRock Therapeutics.
- Total investments:
- 45
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Juergen Eckhardt invests in
Stages Juergen Eckhardt invests in
Countries Juergen Eckhardt invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 23 (51%)
- Health Care 14 (31%)
- Therapeutics 10 (22%)
- Agriculture 9 (20%)
- Life Science 6 (13%)
Stage
- Series A 15 (33%)
- Series B 10 (22%)
- Series C 5 (11%)
- Venture - Series Unknown 4 (9%)
- Seed 3 (7%)
Country
- United States 27 (60%)
- Canada 2 (4%)
- Germany 1 (2%)
- United Kingdom 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ukko is a biotech firm focused on creating safe immunotherapies for quickly addressing allergies and other immune-related disorders. The company utilizes a unique technology platform that combines computational protein design with mRNA/LNP delivery to alter allergenic proteins. This approach seeks to mitigate or eliminate the risks of severeallergic reactions while eliciting a protective immune response. The Company is focused on changing the approach to prevent allergic reactions at the molecular level, striving to offer a safer and more targeted alternative to conventional desensitization techniques. This will lessen the treatment burden while meeting the critical needs of those vulnerable to severe allergic reactions to peanuts, with possibilities for extending the solution to other major allergens like milk, tree nuts, and respiratory triggers. | $45M / Series C / Jan 08, 2026 | ||
| NuCicer is unlocking chickpea’s full potential - transitioning it from “interesting ingredient” to “staple superfood” by launching new varieties with ground-breaking agronomic and quality traits that deliver better nutrition, improved flavor, and more economical ingredients. NuCicer’s technology combines the world's most diverse chickpeabreeding library and their proprietary breeding innovation platform, built on deep roots in plant genetics and machine learning, to create value across the agri-food system. | $11.5M / Series A / Jul 30, 2025 | ||
| GroundTruth Ag is a soil cloud creator specializing in sustainable agricultural management. GroundTruth offers insights into soil management and health as well as near-real-time actionable data layers that cover the physical, chemical, and biological characteristics of the soil. This technology allows farmers to obtain accurate soil informationwhile also offering carbon creditors low-cost, hyper-accurate verification. | $24M / Venture - Series Unknown / Nov 19, 2024 | ||
| EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide. | $191M / Series D / Sep 04, 2024 | ||
| GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars. | $60.3M / Series B / Jul 19, 2024 | ||
| Huma is a global health technology company that provides a modular platform to support digital 'hospitals at home' across different disease areas. Its platform combines predictive algorithms, digital biomarkers, and real-world data to advance proactive, predictive care and research.The company was founded in 2011 and is headquartered inLondon, England. | $80M / Series D / Jul 16, 2024 | ||
| NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. | $42.5M / Series B / Feb 14, 2024 | ||
| Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class. | $30M / Series B / Feb 13, 2024 | ||
| ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $50M / Series B / Sep 19, 2023 | ||
| ChrysaLabs has developed a real-time, portable and accurate soil fertility assessment technology to enable growers and agronomists to better managed their fertilizers and increase their yield. | $11.2M / Series A / May 09, 2023 | ||
| See all 45 investments → | |||
Co-Investors
About Leaps by Bayer
Leaps is the strategic impact investment unit of Bayer. By accelerating transformative biotechnologies, we aim to shift key paradigms in life science, changing the world for better. In health, we pursue breakthroughs that could set new standards in medical care, moving from treating symptoms to curing or preventing diseases. In agriculture, we drive innovations that could nourish a growing population while restoring the planet. It was founded in 2015 and headquartered in Leverkusen, Nordrhein-Westfalen.
Leaps by Bayer Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Juergen Eckhardt
SVP and Head
|
|||
Ryan Teksten
Director, Venture Investments
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Juergen Eckhardt invest in?
Juergen Eckhardt invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 45 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Juergen Eckhardt?
Public channels for Juergen Eckhardt include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Juergen Eckhardt last invest?
The most recent investment recorded for Juergen Eckhardt closed in Jan 2026. Shizune tracks 45 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
